Is population screening for abdominal aortic aneurysm cost-effective?

Ehlers, Lars; Sørensen, Jan; Jensen, Lotte Groth; Bech, Merete; Kjolby, Mette

Published in:
BMC Cardiovascular Disorders

DOI:
10.1186/1471-2261-8-32

Publication date:
2008

Document version
Final published version

Document license
CC BY

Citation for published version (APA):
Ehlers, L., Sørensen, J., Jensen, L. G., Bech, M., & Kjolby, M. (2008). Is population screening for abdominal aortic aneurysm cost-effective? BMC Cardiovascular Disorders, 8, [32]. https://doi.org/10.1186/1471-2261-8-32

Terms of use
This work is brought to you by the University of Southern Denmark through the SDU Research Portal. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply:

• You may download this work for personal use only.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying this open access version

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim. Please direct all enquiries to puresupport@bib.sdu.dk

Download date: 27. Apr. 2021
Is population screening for abdominal aortic aneurysm cost-effective?

Lars Ehlers*1, Jan Sørensen2, Lotte Groth Jensen3, Merete Bech3 and Mette Kjølby3

Address: 1Institute of Public Health, Aarhus University, Denmark, 2Centre for Applied Health Services Research and Technology Assessment, University of Southern Denmark, Denmark and 3Centre for Public Health, Denmark

Email: Lars Ehlers* - lars.ehlers@stab.rm.dk; Jan Sørensen - jas@cast.sdu.dk; Lotte Groth Jensen - lotte.groth@stab.rm.dk; Merete Bech - merete.bech@stab.rm.dk; Mette Kjølby - mette.kjoelby@stab.rm.dk

* Corresponding author

Abstract

Background: Ruptured abdominal aortic aneurysm (AAA) is responsible for 1–2% of all male deaths over the age of 65 years. Early detection of AAA and elective surgery can reduce the mortality risk associated with AAA. However, many patients will not be diagnosed with AAA and have therefore an increased death risk due to the untreated AAA. It has been suggested that population screening for AAA in elderly males is effective and cost-effective. The purpose of this study was to perform a systematic review of published cost-effectiveness analyses of screening elderly men for AAA.

Methods: We performed a systematic search for economic evaluations in NHSEED, EconLit, Medline, Cochrane, Embase, Cinahl and two Scandinavian HTA data bases (DACEHTA and SBU). All identified studies were read in full and each study was systematically assessed according to international guidelines for critical assessment of economic evaluations in health care.

Results: The search identified 16 cost-effectiveness studies. Most studies considered only short term cost consequences. The studies seemed to employ a number of "optimistic" assumptions in favour of AAA screening, and included only few sensitivity analyses that assessed less optimistic assumptions.

Conclusion: Further analyses of cost-effectiveness of AAA screening are recommended.

Background

The annual number of deaths attributable to ruptured abdominal aortic aneurysm (AAA) in Denmark is approximately 400–500 [1,2], corresponding to a mortality of 1–2% of males aged ≥ 65. Overall mortality from ruptured AAA is 80–90%; about half of patients die before they reach hospital [3-5]. Screening programmes that establish diagnosis through ultrasonography and offer elective AAA repair have been advocated because most patients die from undiagnosed ruptured AAA.

Four randomized controlled trials (RCTs) have shown a reduction in AAA-related mortality from screening programs aimed at elderly males [6]. An expected reduction in mortality is not sufficient for a screening program. The program should be acceptable to patients and, if publicly
funded, should be "good value for money". That is, the
decision to introduce such screening programs should be
based on health effectiveness (good health outcomes) and
cost-effectiveness (good value for money) [7].

The purpose of this study was to review cost-effectiveness
studies of screening programs for AAA in elderly males,
and to assess the evidence of cost-effectiveness of such
programs.

Methods

Literature review
Systematic searches were undertaken in NHSEED, Econ-
Lit, Medline, Cochrane, Embase, Cinahl, and two Scandi-
navian health technology assessment databases
(DACEHTA and SBU). The search was from 01.01.1997 to
01.06.2008. Search strategies (in Medline, Cinahl,
Cochrane and Embase) were thesaurus-guided: aortic-
aneurysm-abdominal (MeSH) AND mass-screening
(MeSH), and aortic-aneurysm-abdominal, added sub-
heading "prevention and control". Free text search on
AAA screening was also done. Reference lists of identified
studies and other recent relevant publications were
inspected for additional references.

Inclusion criteria
Only studies in English or Scandinavian languages in
peer-reviewed journals were included. Studies had to be a
full health economic evaluation considering cost and
effects (i.e. analyses of cost-effectiveness, cost-utility, and
cost-benefit) of screening males for AAA.

Analyses
Studies [8-23] were read in full. An assessment was made
according to international guidelines for critical assess-
ment of economic evaluations in health care [7] (Table 1).
Special attention was given to included costs, and an over-
view of relevant cost headings were developed based on
the reviewed articles (Table 2).

Results

Type of economic evaluation
Sixteen studies were included (Table 1). An extended
description of the studies included is available as a web
appendix (see "Additional file 1"). Five were from Scandi-
navia, five from the UK, two from USA and Canada, one
from the Netherlands and one from Japan. Eight studies
were designed as cost-effectiveness studies using objective
health outcomes; eight were cost-utility studies with
health outcomes expressed in quality-adjusted life-years
(QALYs). Six studies were conducted alongside trials
(termed "piggyback" in Table 2): three RCTs, two cohort
studies and one case-control study. Ten studies employed
decision analytic models.

Costs associated with AAA screening
Based on the reviewed studies, the main types of costs
associated with population screening, surveillance and
surgery for AAA have been compiled as shown in Table 2.

There were great variations between the studies in the type
of costs. Most studies included only short-term costs, i.e.
it was implicitly assumed that there is no difference in the
long-term costs between the alternatives. Only three stud-
ies [8,15,18] included long-term costs. The MASS study
[8] and Soisalon-Soininen et al. [15] included costs of
hospital and community care in a follow-up period of 4
years and 17 years, respectively. This included costs of
hospital readmissions, visits to the general practitioner,
outpatient attendances, and variations in patient path-
ways due to surgical complications (e.g. dialysis-depend-
tent renal failure, stroke, myocardial infarction, and major
amputation). Henriksson et al. [18] included an estimate
of the average additional annual health care cost after sur-
gery for AAA for the remaining lifetime of patients.

All studies included the costs of invitation to screening,
ultrasonography, and surgery. Only three of the 16 studies
included private cost to patients (e.g. transportation,
time) [14,17,18]. No study included costs of social serv-
ices (e.g. home help, nursing homes).

Cost amount varied considerably between studies (data
not shown). An example is the cost of ultrasonography in
the MASS study [8], which was more than double the cost
in the study by Lindholt et al. [10] (even if adjusting for
different cost year). Another example was transportation
cost (mobile screening team), which varied by more than
fourfold. The cost of surgery also varied. Differences in
cost estimates can be partly explained by the different
organizational arrangements and different circumstances
due to geography. All studies lacked detailed reporting of
cost estimates, and offered only limited transparency in
cost calculations.

Organizational assumptions underpinning economic
calculations
Ultrasonography is the "gold standard" for AAA screening,
and has been used in all AAA trials and decision analytic
models. All studies assumed that ultrasonography was
done by a mobile team of hospital specialists. Surveillance
of patients with small AAAs was assumed to be handled
by the same team. There were differences with regard to
the: (i) number and type of screening locations; (ii) aver-
age distances of travel for the team and patients; and (iii)
role of the general practitioner. Organizational models in
all studies were described only superficially, which
restricted transferability.
Table 1: Studies of cost-effectiveness of AAA screening

| Nr. | Study                          | Alternative programs                                      | ICER*                  | Comments                                                                                     |
|-----|--------------------------------|-----------------------------------------------------------|------------------------|---------------------------------------------------------------------------------------------|
| 1   | MASS 2002 (UK) [8]             | Screening of men aged 65–74 years vs. no systematic screening strategy | GBP 28 400 per gained life-year or GBP 36 000 per QALY Price level: year 2000 | Costs outside the health care sector not included. Different discount rates used for costs and effects. QOL after elective surgery assumed to be similar to normal population. |
| 2   | Kim et al. 2008 (UK) [9]       | Screening of men aged 65–74 years vs. no systematic screening strategy | USD 19 500 per gained life-year Price level: year 2004–05 | Only short-term hospital costs included. QOL after elective surgery assumed to be similar to normal population. |
| 3   | Lindholt et al. 2006 (DK) [10] | Screening of males aged 65–73 years vs. no systematic screening strategy | GBP 6 090 per gained life-year or GBP 10 793 per saved life Price level: year 2004 | Only short-term hospital costs included. Costs and health effects not discounted. |
| 4   | Wilmink et al. 2003 (UK) [11]  | Screening of males aged >50 years vs. no systematic screening strategy | USD 1 173 per gained life-year Price level: year 1995 | Only short-term hospital costs included. Costs and health effects not discounted. |
| 5   | Hobbs et al. 2004 (UK) [12]    | Screening of males aged >50 years vs. no systematic screening strategy | GBP 375–655 per gained life-year Price level: year? | Only short-term hospital costs included. Costs and health effects not discounted. |
| 6   | Ishikawa et al. 2004 (JP) [13] | Screening of males and females aged >60 years vs. no systematic screening strategy | USD 2 366 per detected AAA Price level: year? | Only short-term hospital costs included. Costs and health effects not discounted. |
| 7   | Lindholt et al. 2002 (DK) [14] | Screening of males aged 65–73 years vs. no systematic screening strategy | DKK 7 540 per gained life-year or DKK 67 855 per saved life Price level: year 1998 | Only short-term hospital costs included. Costs and health effects not discounted. Long-term survival after elective surgery is assumed to be similar to normal population. Data for males aged 65–73 years are used as estimates for 65-year-old males. |
| 8   | Soisalon et al. 2001 (FI) [15] | Screening of first-degree relatives vs. no systematic screening strategy | USD 6 200 per gained life-year Price level: year 1987–89 | Targeted screening of familial AAA. Only hospital costs included. |
| 9   | Kim et al. 2007 (UK) [16]      | Screening of males aged 65 years vs. no systematic screening strategy | GBP 510 per gained life-year or GBP 676 per QALY Price level: year 2000 | Only short-term hospital costs included. Long-term survival and QOL after elective surgery is assumed to be similar to normal population. Data for males aged 65–73 years are used as estimates for 65-year-old males. |
| 10  | Wanhainen et al. 2005 (SE) [17]| Screening of males at age 60, 65 or 70 years vs. no systematic screening strategy | USD 10 474 per gained life-year or USD 13 900 per QALY (results for +65 year old) Price level: year 2003 | Only short-term hospital costs and costs of lost time and travelling due to screening included. QOL after elective surgery assumed to be similar to normal population. Data for males aged 65–74 years (pooled estimates from heterogeneous studies) used as estimates for 65-year-old males. |
| 11  | Henrikson et al. 2005 (SE) [18]| Screening of men aged 65 years vs. no systematic screening strategy | EUR 7 760 per gained life-year or EUR 9,700 per QALY Price level: year 2003 | QOL after elective surgery assumed to be similar to normal population. Data for males aged 65–74 years (pooled estimates from heterogeneous studies) used as estimates for 65-year-old males. |
| 12  | Boll et al. 2003 (NL) [19]     | Screening of males aged 60–65 years vs. no systematic screening strategy | EUR 1 176 per gained life-years Price level: year 1997 | Only short-term hospital costs included. Long-term survival after elective surgery assumed to be similar to normal population. |
| 13  | Lee et al. 2002 (US) [20]      | Screening of males aged 70 years vs. no systematic screening strategy | USD 11 215 per QALY Price level: year? | Only short-term hospital costs included. Long-term survival and QOL after elective surgery assumed to be similar to normal population. |
Economic evaluations alongside trials (short-term cost-effectiveness)

Six economic evaluations were conducted alongside trials using patient-level data in evaluation of the cost-effectiveness of AAA screening. Three studies [8-10] used patient-level data from a RCT with a time perspective of 4, 5 and 7 years. The MASS study [8] estimated the incremental cost-effectiveness ratio (ICER) to be GBP 28 400 per gained life-year, or approximately GBP 36 000 per QALY. The authors concluded that this result was at the margin of acceptability according to National Health Service thresholds, but they expected cost effectiveness to improve over time. Kim et al. [9] used data from MASS trial after 7 years of follow up to estimate ICER at USD19 000; however this study only included short term hospital costs. Lindholt et al. [10] estimated ICER to be GBP 6 090 per gained life-year without long-term cost and discounting. The three other studies that used patient-level data (from local cohort studies or case-control studies) estimated ICER to be in the same order of magnitude, and suggested that screening may be cost-effective [11-13].

Economic evaluations using decision analytic modelling (long-term cost-effectiveness)

Ten studies used decision analytic modelling to estimate long-term cost-effectiveness of AAA screening. The general conclusion from these studies was that AAA screening seems to be cost-effective, but the ICER varies considera-

Table 1: Studies of cost-effectiveness of AAA screening (Continued)

| Study | Authors and Year | Screening Strategy | ICER | Price Level | Notes |
|-------|------------------|--------------------|------|-------------|-------|
| 14    | Conelly et al. 2002 (CA) [21] | Screening of males and females aged >50 years vs. no systematic screening strategy | CAD 741 per QALY | Price level: year? | Only short-term hospital costs included. Long-term survival and QOL after elective surgery assumed to be similar to normal population. |
| 15    | Montreuil et al. 2008 (CA) [22] | Screening of males aged 65 years vs. no systematic screening strategy | CAD 6 194 per QALY | Price level: year 2005 | Only short-term hospital costs included. QOL after elective surgery assumed to be similar to normal population. Data for males aged 65–74 years used as estimates for 65-year-old males. |
| 16    | Silverstein et al. 2005 (US) [23] | Screening of males at age 65 years vs. no systematic screening strategy | USD 19 720 per QALY | Price level: year? | Only short-term hospital costs included. Long-term survival and QOL after elective surgery assumed to be similar to normal population. Data for males aged 65–74 years used as estimates for 65-year-old males. |

* ICER is not comparable between studies because results are based on different assumptions and methods

Table 2: Main types of costs associated with AAA screening

1. Invitation to screening (and re-invitations for non-attenders).
   Includes clerical staff time, postage and stationery, cost of obtaining patient details, office space and equipment, overheads.

2. Ultrasonography (and re-scan and surveillance).
   Includes clinic staff time, staff travel cost, disposables, annuitization of capital expenditures, maintenance and service contracts, office space/charge of locations.

3. Surgery (pre-assessments for suitability, elective aneurysm repairs (as well as emergency surgery for ruptures) hospitalization).
   Includes theatre time, time spent in intensive care and general ward, drugs, blood products, non-pathological investigations, graft inserted, and overheads.

4. Hospital and community care (short and long term)
   Includes readmissions, graft surveillance and secondary procedures after surgery, visits to general practitioner, outpatient attendances and patient pathways due to surgical complications (dialysis-dependent renal failure, stroke, myocardial infarction, and major amputation).

5. Patient and family resources.
   Includes transportation expenditures, medicine and time cost.

6. Resources in other sectors.
   Includes social services (e.g. home help and nursing homes).
bly and a direct comparison of results is not possible due to considerable differences in the analytical basis. Studies employed different methods (types of model, time frame, and perspective) and different assumptions (sources of evidence for effect and transition probabilities, and cost assumptions) for their analysis.

**Assumptions about screening effectiveness**

Half of the modelling studies were based on evidence of the effectiveness of AAA screening from RCTs. All used evidence from screening a group of men (typically males aged 65–79 years) to estimate effectiveness of screening a single age group (typically 65-year-old males). Other modelling studies were based on effectiveness data from trials with lower levels of evidence.

In general, the main advantage of screening is assumed to be an increase in the number of patients diagnosed with AAA and offered elective AAA repair. All studies assumed a constant risk of rupture depending on AAA size. The gained life-years/QALYs arise because the total number of elective surgeries increases, and the need for emergency surgery of ruptured AAA is therefore assumed to decrease.

**Assumptions about long-term survival after elective surgery**

Most of the studies used national mortality rates for the average population as proxy for long-term survival after elective surgery, but some studies made more realistic assumptions. Wanheinen et al. [17] assumed that the mortality in treated AAA patients were 2.05 times the rates in the age-matched normal population because of high comorbidity rates in AAA patients. Lee et al. [20] adjusted the annual mortality rates to take account of expected excess mortality in patients with dialysis-dependent renal failure, stroke, myocardial infarction or major amputation. Henriksson et al. [18] and Soisalon-Soininen et al. [15] used local mortality data for AAA patients for 5 years and 17 years, respectively, and carried out survival analysis using statistical methods (Weibull or actuarial) in their estimation of life-years gained.

**Assumptions about quality of life (QOL) and QALY after elective surgery**

Seven of the decision analytic studies calculated ICER as the incremental cost per gained QALY. These studies implicitly assumed that postoperative QOL (and after recovery) was similar to the QOL of the age-matched general population. Only one study (Lee et al. [20]) included the reduced QOL experienced by patients with major surgical complications.

Only two studies carried out sensitivity analyses of QOL assumptions. Wanheinen et al. [17] assumed a short-term reduction in QOL due to anxiety experienced before untrasoundography. They estimated a reduction of 5% in the first-year QALY, which was outweighed by uncertainty in the long term. Henriksson et al. [18] did a multiway sensitivity analysis in which QOL was allowed to vary stochastically according to a pre-specified statistical distribution, but it was not possible to distinguish the effect.

**Discussion**

The purpose of this review was to carry out a critical assessment of cost-effectiveness studies of screening older males for AAA. Based on our review of 16 studies, it seems that most of the health economic analyses of screening for AAA employed "optimistic" assumptions about the cost effectiveness of AAA screening.

The MASS cost-effectiveness study at four years [8] has the highest quality, but this single study does not provide enough information to assess the cost-effectiveness of AAA screening. MASS did not collect information on QALY gains, and endovascular aortic aneurysm repair was not used in the trial. The time perspective in MASS was four years, and a modelling approach is needed to assess long-term cost consequences and perform detailed sensitivity analyses.

In all published decision analytic models of AAA screening hypothetical patients with an AAA ≥ 5.5 cm were assumed to face a constant probability of rupture (average for males aged 65–79 years) no matter how many years they have had a large AAA. In cohort simulations such a constant probability of rupture gives a wrong distribution of death over time and a mean age of males having emergency surgery for ruptured AAA that is much too low. For instance in Denmark the mean age of death from ruptured AAA is 76 years (range 65–92) for males aged ≥ 65. One way to "build memory" into a model is to implement time dependency, but none of the modelling studies seems to have done so. Accordingly, when underestimating the age of males dying of ruptured AAA in the non-screening group the calculated number of "gained life-years" due to screening and avoiding ruptures is too high.

Most of the health economic studies of AAA screening only included short term hospital costs. Major implications for society due to comorbidity and severe surgical complications (e.g. stroke or chronic renal failure) were not included because most studies did not consider cost after hospital discharge. Patient pathways after such events can be very costly [24]. Furthermore, screening might induce extra long term cost of treatment of those unfit for surgery [9].

Economic evaluations did not incorporate evidence that the lives of tobacco smokers are generally shorter than...
those of the general population, and that they have a higher demand for health services (i.e. higher social and health care costs) and a lower QOL in the remaining life-years [25-27] (>90% of patients with AAA have a history of smoking [3-5]).

There has been considerable interest in smoking cessation programmes during the last decade. Successes in reducing the number of smokers have been linked to potential savings in future health care costs [25-27]. Economic evaluations of AAA screening seem to have ignored the relationship between tobacco smoking and AAA incidence. The incidence may even fall to levels that render population screening ineffective in terms of lives saved, let alone cost.

There is a lower prevalence of large AAAs in males who have never smoked, so the potential benefit from screening non-smokers is small. The USA Preventive Services Task Force recommends AAA screening in male smokers only for this reason [28]. The possibility of screening only male smokers could probably increase cost-effectiveness, although some authors argue the benefit from targeted screening is marginal compared with population screening [17].

All cost-utility studies assumed that patients with AAA could return to a QOL comparable with the average population: there is only poor evidence for this assumption. None of the randomised trials of AAA screening have collected evidence about QOL before and after screening and elective surgery in the screening group compared to the average population (i.e. the non-screening group). Only studies of QOL with poorer designs have been published.

Furthermore, the clinical literature of QOL after elective repair that are being referred to seems to be in conflict with public health evidence that smokers experience a lower QOL in their remaining years of life compared to the average population. At least more sensitivity analyses should have been done to evaluate the possibility of lower QOL due to comorbidity and severe surgical complications such as chronic renal failure, major amputation or stroke.

Various other factors likely to reduce cost-effectiveness were ignored in the economic evaluations. In most cases, cost calculations were based on open repair and not on endovascular aneurysm repair. Despite lack of evidence of cost-effectiveness, this method of treating AAAs is being used increasingly in many countries. It may reduce early mortality more effectively, but it may substantially reduce the cost-effectiveness of screening [29].

The possibility is that *ad hoc* detection of AAA cases will gradually increase as imaging (mostly ultrasonography) becomes more widely utilized for other reasons. This may reduce the prevalent pool of undiagnosed AAAs and hence screening effectiveness [30].

Our findings are in accordance with those of Campbell et al. [31]; they reviewed cost-effectiveness studies of AAA screening published between 1989 and 2003. They found that "eight of the nine population screening models have incorporated at least two assumptions, which would artificially favour a screening programme". This review by Campbell et al. has not been updated; the search period ended in 2003, and they excluded studies conducted alongside trials, which is a major source of evidence for cost-effectiveness. Our review includes ten new cost-effectiveness analyses, and only four studies overlap. Our review gives the "whole" picture of cost-effectiveness of AAA screening, which have not been presented before.

The individual conclusions of cost effectiveness cannot be rejected on the basis of this systematic review, but we can seriously challenge the assumptions on which the studies of cost-effectiveness are based. Our review leaves little doubt that the reported cost-effectiveness ratios of AAA screening in most cases have been too low.

Our findings should have implications for future research recommendations in cardiovascular medicine and surgery. It appears that existing analyses have overrated the advantages of AAA screening in terms of the expected number of gained life-years/QALYs and cost of a screening programme. Different patient pathways after surgery are ignored, and sensitivity analyses of long-term QOL after surgery are not satisfactory.

We therefore strongly recommend that an "updated" cost-effectiveness analysis should be carried out based on more realistic assumptions.

**Conclusion**

This review indicates that most of the existing health economic evaluations have employed a number of "optimistic" assumptions in favour of AAA screening, and included only few sensitivity analyses that assessed less optimistic assumptions. Further analyses of cost-effectiveness of AAA screening are recommended.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

LE carried out the main study and drafted the manuscript. LS, MB, LGJ and MK participated in the analyses and dis-
cussion of the results. LGJ also carried out the literature search. All authors approved the final manuscript.

Additional material

Additional file 1

Studies of cost-effectiveness of AAA screening. The additional file is an extended version of Table 1 Studies of cost-effectiveness of screening for AAA. The extended version includes further details on the methods used and the primary sources of data for outcome.

Click here for file

http://www.biomedcentral.com/content/supplementary/1471-2261-8-32-S1.doc

Acknowledgements

None.

References

1. Danish Vascular Registry: Annual report for 2006 [http://www.kar-base.dk].
2. Lindholt JS: Considerations and experiences of screening for abdominal aortic aneurysms. In PhD Thesis Copenhagen: Fadl's Forlag; 1998.
3. Medical Advisory Secretariat, Ministry of Health and Long-Term Care: Ultrasound screening for abdominal aortic aneurysm. Health technology policy assessment Ontario, Canada; 2005.
4. Cornuz J, Pinto CS, Tevarai H, Egger M: Risk factors for asymptomatic abdominal aortic aneurysm. Eur J Public Health 2004, 14:343-349.
5. Cronenwett JL, Likosky DS, Russel MT, Eldrup-Jørgensen J, Stanley AC, Nolan BW: A regional registry for quality assurance and improvement: The Vascular Study Group of Northern New England (VSGNNE). J Vasc Surg 2007, 46:1093-1102.
6. Cosford PA, Leng GC: Screening for abdominal aortic aneurysm. Cochrane database of systematic reviews 2007.
7. Drummond M, Schuler J, Torrance GW, O'Brien B, Stoddart GL: Methods for the evaluation of health care programmes Oxford: Medical Publications; 2005.
8. MASS Study Group: Multicentre aneurysm screening study (MASS): cost effectiveness analysis of a population screening program. J Vasc Surg 2003, 38:72-77.
9. Kim LG, Scott AP, Ashton HA, Thompson SG: A sustained mortality benefit from screening abdominal aortic aneurysm. Ann Intern Med 2007, 146:699-706.
10. Lindholt JS, Juul S, Fasting H, Henneberg EW: Cost-effectiveness analysis of screening for abdominal aortic aneurysms based on five year results from a randomised hospital based mass screening trial. Eur J Vasc Endovasc Surg 2006, 32:9-15.
11. Wilimink ABM, Quick CRG, Hubbard CS, Day NE: Effectiveness and cost of screening for abdominal aortic aneurysm: results of a population screening program. J Vasc Surg 2003, 38:72-77.
12. Hobbs S, Claridge M, Drage M, Quick C, Bradbury A, Wilimink A: Strategies to improve the effectiveness of abdominal aortic aneurysm screening programmes. J Med Screen 2004, 11:93-96.
13. Ijihikawa S, Takahashi T, Sato Y, Suzuki M, Ohki S, Chihana K, Mohara J, Nameki T, Morishita Y: Screening cost for abdominal aortic aneurysms: Japan-based estimates. Surg Today 2004, 34:828-831.
14. Lindholt JS, Juul S, Fasting H, Henneberg EW: Hospital costs and benefits of screening for abdominal aortic aneurysms. Results from a randomised population screening trial. Eur J Vasc Endovasc Surg 2002, 23:55-60.
15. Soisalon-Soininen S, Rissanan P, Pentikäinen T, Mattila T, Salo JA: Cost-effectiveness of screening for familial abdominal aortic aneurysms. Vasa 2001, 30:262-270.
16. Kim LG, Thompson SG, Briggs AH, Buxton MJ, Campbell HE: How cost-effective is screening for abdominal aortic aneurysms? J Med Screen 2007, 14:46-52.
17. Wanheinen A, Lundkvist JV, Bergquist D, Björck M: Cost-effectiveness of different screening strategies for abdominal aortic aneurysm. J Vasc Surg 2005, 41:741-51.
18. Henriksson M, Lundgren F: Decision-analytical model with lifetime estimation of costs and health outcomes for one-time screening for abdominal aortic aneurysm in 65-year-old men. Br J Surg 2005, 92:976-983.
19. Boll APM, Severens JL, Verbeek ALM, Vliet JA: Mass screening on abdominal aortic aneurysms in men aged 60 to 65 in the Netherlands. Impact on life expectancy and cost-effectiveness using a Markov model. Eur J Vasc Endovasc Surg 2003, 26:76-80.
20. Lee TY, Korn P, Heller JA, Kilaru S, Beavers FP, Bush HL, Kent KC: The cost-effectiveness of a “quick-screen” program for abdominal aortic aneurysm. Surgery 2002, 132:399-407.
21. Connelly JB, Hill GB, Millar WJ: The detection and management of abdominal aortic aneurysm: a cost-effectiveness analysis. Clin Invest Med 2002, 25:127-33.
22. Montreuil B, Brophy J: Screening for abdominal aortic aneurysms in men: a Canadian perspective using Monte Carlo-based estimates. Can J Surg 2008, 51:23-34.
23. Silverstein MD, Pitts SR, Chaikof EL, Ballard DJ: Abdominal aortic aneurysm (AAA): cost-effectiveness of screening, surveillance of intermediate-sized AAA, and management of symptomatic AAA. BJUM Proceedings 2005, 18:345-367.
24. Manns BJ, Mendelsohn DC, Taub KJ: The economics of end-stage renal disease care in Canada: incentives and impact on delivery of care. Int J Health Care Finance Econ 2007, 7:149-169.
25. Rasmussen SR, Prescott E, Sorensen T, Søgaard J: The total lifetime costs of smoking. Eur J Public Health 2004, 14:93-100.
26. Kaper J, Wagene E, Schayck CP, Severens JL: Encouraging smokers to quit. The cost effectiveness of reimbursing the costs of smoking cessation treatment. PharmacoEconomics 2006, 24:453-464.
27. Olsen KR, Bilde L, Juhl HH, Kjær JT, Mosbech H, Ewald T, Rasmussen M, Hildakids H: The cost-effectiveness of the Danish smoking cessation interventions. Eur J Health Econ 2006, 7:255-264.
28. US Preventive Services Task Force: Screening for abdominal aortic aneurysm: recommendation statement. Ann Int Med 2005, 142:198-202.
29. Michaels JA, Drury D, Thomas SM: Cost-effectiveness of endovascular abdominal aortic aneurysm repair. Br J Surg 2005, 92:960-967.
30. Norman PE, Ramrozzik K, Lawrence-Brown MM, Le MT, Spencer CA, Tuohy RJ, Parson RW, Dickinson JA: Population based randomised controlled trial on impact of screening on mortality from abdominal aortic aneurysm. BMJ 2004, 329:1259-1266.
31. Campbell H, Briggs A, Buxton M, Kim L, Thompson S: The credibility of health economic models for health policy decision-making: the case of population screening for abdominal aortic aneurysm. J Health Serv Res Policy 2007, 12:11-17.

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2261/8/32/prepub